Weight Loss Jabs Slow Alzheimer's Decline

Researchers have discovered that a weight loss jab, liraglutide, may offer significant benefits for individuals with Alzheimer's disease, potentially slowing cognitive decline by 50%. This GLP-1 agonist, also marketed as Saxenda, mimics natural hormones to regulate appetite and blood sugar.

Initial findings from a study involving 169 participants indicate that daily injections of liraglutide over a year led to a notable reduction in brain volume loss. While not impacting glucose metabolism directly, the drug appears to protect brain volume, possibly by reducing inflammation and toxic protein build-up.

Although liraglutide is already prescribed for weight management, its potential as an Alzheimer's treatment requires further investigation. Study authors stress the need for long-term research to fully establish its therapeutic role for neurodegenerative conditions, even as accessibility to such drugs remains a global concern.